JPET #216671

Introduction
Selective sigma-1 (σ 1 ) receptor antagonists typically attenuate cocaine's locomotor stimulatory effects through mechanisms that include direct blockade of cocaine's agonist actions at the site, modulation of σ 1 receptor interactions with dopaminergic and glutamatergic signal transduction pathways that are activated by cocaine, and inhibition of the neuronal adaptations and changes in gene expression that occur as a consequence of cocaine administration (Matusumoto et al., 2003; . Thus, small molecule σ 1 receptor antagonists are under study for pharmacotherapy of psychostimulant abuse (Robson et al., 2012) . Cocaine is also a sigma-2 (σ 2 ) receptor agonist (Garcés-Ramírez et al., 2011) , and selective σ 2 receptor antagonists can also inhibit cocaine-induced hyperactivity (Lever et al., 2014) . Roles played by σ 2 receptors in cocaine's behavioral effects, however, are less well defined than those for σ 1 receptors. Akunne and colleagues (1997) characterized PD144418 ( PD144418 was classified as a σ 1 receptor antagonist based upon several assays, including the ability to attenuate mescaline-induced scratching in mice. Surprisingly, Akunne et al. (1997) reported that PD144418 did not block cocaine's motor stimulatory effects in mice. Parallel studies they conducted using BMY14802, one of the first σ receptor antagonists shown to attenuate cocaine's motor stimulatory effects (Menkel et al., 1991) , also showed no effect. Akunne et al. (1997) noted that there was no clear rationale for the discrepancy.
A number of recognition sites affect cocaine stimulation of motor function (Sora et al., 2010) . Therefore, the σ receptor antagonist actions of a given ligand might be masked by the involvement of other pathways. For instance, haloperidol exhibits strong dopaminergic actions JPET #216671 5 in addition to antagonism of σ receptors, and does not attenuate cocaine-induced locomotor hyperactivity (Witkin et al., 1993; Xu et al., 2010) . PD144418, however, shows no significant in vitro affinity for dopamine, serotonin or opioid receptors, as well as many other recognition sites.
On the other hand, binding interactions of PD144418 with monoamine transporters, sites known to influence cocaine's behavioral actions (Hall et al., 2009; Sora et al., 2010) , were not investigated in the initial screening assays.
There have been few subsequent studies of PD144418 despite its exceptionally high affinity and selectivity for σ 1 receptors. Gund et al. (2004) appear to have been reported since the original work of Akunne and colleagues (1997) .
In the present study, we confirmed the high Lever et al., 2012) and [ 125 I ]RTI-121 (3β-(4-iodophenyl)tropan-2β-carboxylic acid isopropyl ester; Lever et al., 1996) were prepared as previously described. Tritiated radioligands were obtained from PerkinElmer Life Sciences, Inc. (Boston, MA). Other chemicals and solvents were the best grades commercially available, and were used as received. Drug concentrations are given in molar units. Mass amounts designated refer to the salt or free base forms listed above.
Animals. Male CD-1® mice, typically 23 -28 g (Charles River Laboratories
International, Inc.; Wilmington, MA), were group housed in temperature-and humidity-controlled quarters under a 12-h / 12-h, light / dark cycle with free access to standard rodent chow and water. Experiments were conducted during the light phase of the cycle after animals had acclimated for at least one week. Studies were performed in compliance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National
Institutes of Health, and with prior approvals from the Institutional Animal Care and Use
Committees of the University of Missouri and the Harry S. Truman Memorial Veterans' Hospital.
In vitro binding studies. Stock solutions of PD144418 oxalate were prepared in DMSO at ambient temperature, with serial dilutions made using pH 7.4 Tris-HCl buffer (50 mM) containing 0.01% bovine serum albumin (BSA). Final assay concentrations of DMSO were kept at or below 1%. Stock and serial dilutions of haloperidol were prepared in distilled water containing 1% ethanol and 0.1% acetic acid. PD144418 stocks and serial dilutions were also prepared in this aqueous vehicle, but vigorous heating was required, suggesting potential issues with precipitation or adsorption to glass surfaces. Radioligands, as well as brain membranes, JPET #216671
were formulated in the Tris-HCl buffers (50 mM) appropriate for each experiment. Assays were terminated by addition of ice-cold buffer followed by manifold filtration through glass fiber filters (GF/B) that had been pretreated with polyethyleneimine (0.5%). Tubes and filter paper discs were washed (3 x 5 ml) with cold buffer, and the discs were dried under vacuum. μ M) to define non-specific binding, in membranes prepared from whole CD-1® mouse brains, harvested after euthanasia by cervical dislocation, as previously described (Lever et al., 2012) .
Binding assays for monoamine transporters were performed, using established procedures, in membranes prepared from fresh CD-1® mouse brains. In brief, DAT assays used [ 125 I ]RTI (15 pM) in striatal membranes with GBR12909 (0.5 μ M) to define non-specific binding (Boja et al., 1995) . NET assays used [ (Hirano et al., 2005) .
For the six types of binding assays performed, specific radioligand binding was 77% -92% of the total binding. Experiments were conducted in duplicate or in triplicate, and replicated three to six times. Data were analyzed by non-linear regresssion using a sigmoidal fourparameter logistic fit (Prism 6.0c; GraphPad Software, Inc.; La Jolla, CA (Lever et al., 2012) , and 0.12 nM for [ 125 I ]RTI (Boja et al., 1995) .
In vivo binding studies. Dose-response data for inhibition of [ 125 (Lever et al., 2012 Animals were euthanized by cervical dislocation 30 min after radioligand administration, whole brain removed, and samples of cerebellum, striatum and olfactory tubercles were dissected, weighed and counted along with standards of the injected dose as described above.
Radioactivity levels in cerebellum served to define non-specific binding (Lever et al., 1996; Desai et al., 2005) .
Two-tailed, unpaired t-tests at the 95% confidence level, or ANOVA (α = 0.05) with post hoc Dunnett's or Tukey's tests (Prism 6.0c), were employed to analyze potential differences between groups. Dose-response data were fit using an unconstrained sigmoidal regression algorithm, changes in occupancy as a function of time were fit using a one-phase exponential decay curve, and the regional brain uptake of [ as between-group factors, and Time (twelve 5-min intervals) as a within-subjects factor. Where appropriate, (p < 0.05), simple main effect and Tukey's post-hoc analyses were performed. To evaluate the dose-response relationship, total distance traveled during the 60-min period after cocaine injection was summed for each group of mice, and data were analyzed by non-linear regression using an unconstrained sigmoidal fit (Prism 6.0c). For the follow-up experiment, a 3-way RM-ANOVA was performed with PD144418 Dose (0 and 3.16 µmol/kg), Cocaine Dose (0 and 99 µmol/kg) as between-group factors, and Time as a within-subject factor.
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Results
In vitro binding studies. Binding affinities of PD144418 for the σ receptor subtypes determined in the present study, along with those of Akunne et al. (1997) , are given in Table 1 .
Data from side-by-side determinations for haloperidol in the two studies are included for comparison. We observed a σ 1 receptor K i of 0.46 ± 0.04 nM for PD144418 against The affinity of PD144418 for monoamine transporters was tested using established binding assays in membranes prepared from mouse brain (Table 1) . A weak interaction, K i = 9,038 nM, was determined for PD144418 binding to striatal DAT that was accompanied by a steep Hill slope (n H 1.60 ± 0.06). No appreciable affinity was observed for NET and SERT, with K i values > 100,000 nM using cortical and whole brain membranes, respectively.
In vivo binding studies. To define the interactions of PD144418 with of PD144418, levels of tissue radioactivity were significantly reduced by 69% in brain, 63% in heart, 48% in spleen and 63% in lung (ANOVA, Dunnett's).
The regional distribution of [ 125 I ]E-IA-DM-PE-PIPZE in mouse brain, which has not been previously reported, is shown in Fig. 2B . The highest levels of radioligand uptake were in cerebellum, hypothalamus, and the brainstem (pons / medulla, superior / inferior colliculi).
Intermediate levels were observed for the cortical regions, while the lowest levels were noted for striatum, olfactory tubercles and hippocampus. Both PD144418 ( across the regions, and can be used to define non-specific radioligand binding throughout the brain. The PD144418 dosage blocked uptake by 52 -67% across all regions. There were no significant differences between radioactivity levels in the various regions in the presence of BD1063, except for a small differential between the olfactory tubercles as compared to the pons / medulla (ANOVA, Tukey's).
The pattern of distribution shown in Fig. 2B assessed as the difference in %ID / g between these regions, that are rich in the DAT, and that in cerebellum, a brain region with a low density of the sites that can be used as an internal reference for non-specific binding (Lever et al., 1996; Desai et al., 2005) . Mice pretreated with followed by saline were 70% less active than animals that received only saline. There were no significant differences in locomotor activity among the groups of mice that received 0.10, 1.0 3.16 or 10.0 µmol / kg PD144418 followed by saline, and the control group that received only saline injections.
PD144418 treatments produced a dose-dependent attenuation of the locomotor stimulation induced by 66 µmol / kg cocaine (Fig. 4) . Analysis of total distance traveled revealed that mice administered 1.0, 3.16, 10.0 or 31.6 µmol / kg PD144418 followed by cocaine were 40 -85% less active than mice administered saline followed by 66 µmol / kg cocaine ( Fig 4A) . Furthermore, mice administered 31.6 µmol / kg PD144418 and cocaine were less active than mice administered 1.0 µmol/kg PD144418 and cocaine. There was not a significant difference in locomotor activity between the group of mice that received 0.10 µmol / kg PD144418 followed by cocaine, and those that received saline followed by cocaine.
Regarding the time course (Fig. 4B) , there was less activity for mice administered 31.6 µmol / kg PD144418 followed by 66 µmol / kg cocaine than for mice administered saline administered saline and cocaine at the 20 -45 min time points. There was less activity for mice administered 1.0 µmol / kg PD144418 followed by cocaine compared to mice administered saline followed by cocaine at the 20 -35 min time points. However, there were no significant differences in locomotor activity at any time point between the groups of mice that received 0.10 µmol / kg PD144418 followed by cocaine, and those that received saline followed by cocaine.
In a follow-up study, the effect of PD144418 (3.16 µmol / kg) on locomotor stimulation induced by 99 µmol / kg cocaine was assessed. Total distance traveled for the 60 min period after cocaine injection is presented in Fig. 4A . A significant main effect of Cocaine Dose (F (1, 45) = 48.720, P < 0.001) was found, as mice administered cocaine displayed greater activity than mice administered saline. A significant PD144418 Dose x Cocaine Dose also was observed (F (1,35) = 4.549, P = 0.004), although the PD144418 Dose x Cocaine Dose x Time interaction was not significant (F (11,385) = 0.821, P = 0.621). Mice administered 3.16 µmol / kg PD144418 followed by cocaine were less active than mice administered saline followed by cocaine. Thus, PD144418 decreased the locomotor stimulation induced by the lower (66 µmol / kg) and the higher (99 µmol / kg) cocaine doses by 57% and 31%, respectively. occupancy was approximately 70%, and heart occupancy was 68 -88%. Occupancy in the spleen was lower, ranging from 40 -60%. as 4 and 16 h, with respect to the control group of animals that received only saline (ANOVA, Dunnett's). There were no significant differences in locomotor hyperactivity between the PD144418 treatment groups from 15 min -24 h (ANOVA, Tukey's). However, a strong onetailed Pearson correlation (r 2 = 0.94, P = 0.01) was observed for the increase in locomotor hyperactivity with respect to the time after PD144418 administration (data not shown). Fig. 8 depicts the time-response relationships for PD144418 occupancy of cerebral σ JPET #216671
Discussion
The present work addresses the apparent paradox of PD144418 being reported by Akunne et al. (1997) as a potent and selective σ 1 receptor antagonist with no ability to counteract cocaine-induced locomotor hyperactivity. In vitro binding studies, in vivo receptor occupancy studies, and behavioral studies were employed. As discussed below, the binding data confirmed that PD144418 should be considered a selective, high-affinity σ 1 receptor ligand as reported by Akunne and colleagues (1997) , the in vivo studies provided Webster (Menkel et al., 1991) or CD-1® mice (Rodvelt et al., 2011) . Consequently, cocaine dosage is not likely to have had a major impact.
At a practical level, the preparation of stock solutions of PD144418 oxalate in aqueous vehicles requires heat and thorough mixing. This engenders some concern regarding solubility and the potential for drug precipitation. The chemical form of PD144418, salt or free base, was not specified by Akunne et al. (1997) . These investigators reported the same depression of basal locomotor activity by PD144418 that we observed, a finding that requires higher levels of PD144418 (10 -30 mg / kg), and also showed antagonism of mescaline-induced scratching behaviors by PD144418 (3 -30 mg / kg). Thus, Akunne and colleagues (1997) (Kaushal et al., 2011) . occupancy of a variety of recognition sites, including cannabinoid receptors (Gifford et al., 1999) , dopamine D 2 receptors (Wadenberg et al., 2000) , the DAT (Desai et al., 2005) (Bouchard et al., 1996) . Biodistribution data are mean values, n = 4 per group (see panel B). 
